IOL Chemicals Secures NMPA Approval in China for Clopidogrel Bisulfate API
IOL Chemicals & Pharmaceuticals Ltd has received significant regulatory approval for its Active Pharmaceutical Ingredient (API), 'Clopidogrel Bisulfate,' from Chinese authorities. The Centre for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), China, granted the approval on 14th July 2026.This critical regulatory milestone expands IOL Chemicals' reach into the highly regulated Chinese pharmaceutical market. The NMPA approval complements an existing Certificate of Suitability (CEP) that the company holds for Clopidogrel Bisulfate.
The successful attainment of this approval further strengthens the company's overall regulatory portfolio. This achievement enables IOL Chemicals to enhance its presence and access within the specialized Chinese pharmaceutical sector.
IOLCP Stock Price Movement
IOL Chemicals and Pharmaceuticals surged today, gaining 3.20% to close at ₹173.78 as the stock traded strongly in the pharmaceutical sector. The equity saw a strong performance throughout the day, reaching its 52-week high of ₹179 before settling within a trading range that included a volume of 9.03 million shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.